DSG2 and Miyoshi myopathy: Surprisingly, lenalidomide appeared to abrogate the link of poor prognostic effect with high DSG2 MM PC expression at diagnosis (PFS: HR 1.20, CI 0.67–2.13, P = 0.55; OS: HR 1.00, CI 0.41–2.38, P = 0.99) and could suggest a particular benefit in using this or other immunomodulatory drugs for treating DSG2‐high patients (Tables S3 and S4).